{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:35:37Z","timestamp":1792427737933,"version":"4.5.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T00:00:00Z","timestamp":1726099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T00:00:00Z","timestamp":1726099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"DOI":"10.1007\/s00296-024-05714-1","type":"journal-article","created":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T23:43:38Z","timestamp":1726098218000},"page":"2927-2934","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Evaluation of tocilizumab-induced hypofibrinogenemia in rheumatology practice: a retrospective, real-life, single-center experience"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4040-0212","authenticated-orcid":false,"given":"Re\u015fit","family":"Y\u0131ld\u0131r\u0131m","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6543-3905","authenticated-orcid":false,"given":"D\u00f6nd\u00fc \u00dcsk\u00fcdar","family":"Cansu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8133-8278","authenticated-orcid":false,"given":"Mustafa","family":"Dinler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2679-0699","authenticated-orcid":false,"given":"Cengiz","family":"Korkmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,12]]},"reference":[{"key":"5714_CR1","doi-asserted-by":"publisher","first-page":"a028456","DOI":"10.1101\/cshperspect.a028456","volume":"1","author":"T Tanaka","year":"2018","unstructured":"Tanaka T, Narazaki M, Kishimoto T (2018) Interleukin (IL-6) immunotherapy. Cold Spring Harb Perspect Biol 1:10:a028456. https:\/\/doi.org\/10.1101\/cshperspect.a028456","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"5714_CR2","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","volume":"397","author":"RECOVERY Collaborative Group","year":"2021","unstructured":"RECOVERY Collaborative Group (2021) Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 397:1637\u20131645. https:\/\/doi.org\/10.1016\/S0140-6736(21)00676-0","journal-title":"Lancet"},{"key":"5714_CR3","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1007\/s40265-017-0829-7","volume":"7","author":"LJ Scott","year":"2017","unstructured":"Scott LJ (2017) Tocilizumab: a review in rheumatoid arthritis. Drugs 7:1865\u20131879. https:\/\/doi.org\/10.1007\/s40265-017-0829-7","journal-title":"Drugs"},{"key":"5714_CR4","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.jbspin.2016.04.008","volume":"84","author":"N Martis","year":"2017","unstructured":"Martis N, Chirio D, Queyrel-Moranne V, Zenut MC, Rocher F, Fuzibet JG (2017) Tocilizumab-induced hypofibrinogenemia: a report of 7 cases. Joint Bone Spine 84:369\u2013370. https:\/\/doi.org\/10.1016\/j.jbspin.2016.04.008","journal-title":"Joint Bone Spine"},{"key":"5714_CR5","doi-asserted-by":"publisher","first-page":"9050","DOI":"10.1038\/s41598-023-36246-6","volume":"13","author":"T He","year":"2023","unstructured":"He T, Ling J, Yang J (2023) Tocilizumab-induced hypofibrinogenemia in patients with systemic-onset juvenile idiopathic arthritis. Sci Rep 13:9050. https:\/\/doi.org\/10.1038\/s41598-023-36246-6","journal-title":"Sci Rep"},{"key":"5714_CR6","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1007\/s10067-024-06937-0","volume":"43","author":"Q An","year":"2024","unstructured":"An Q, Ma R, Yuan D, Huang J, Luo J, Wang Y et al (2024) Clinical observation of hypofibrinogenemia induced by the treatment of tocilizumab in rheumatic diseases and exploration of risk factor for hypofibrinogenemia. Clin Rheumatol 43:1491\u20131501. https:\/\/doi.org\/10.1007\/s10067-024-06937-0","journal-title":"Clin Rheumatol"},{"key":"5714_CR7","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s00296-019-04268-x","volume":"39","author":"D \u00dcsk\u00fcdar Cansu","year":"2019","unstructured":"\u00dcsk\u00fcdar Cansu D, Demirta\u015f E, Andi\u00e7 N, \u00dcsk\u00fcdar Teke H, Korkmaz C (2019) Is it required to routinely check fibrinogen level in patients with rheumatic diseases on tocilizumab? Case-based review. Rheumatol Int 39:743\u2013750. https:\/\/doi.org\/10.1007\/s00296-019-04268-x","journal-title":"Rheumatol Int"},{"key":"5714_CR8","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.jbspin.2017.02.012","volume":"84","author":"G Vitiello","year":"2017","unstructured":"Vitiello G, Orsi Battaglini C, Radice A, Carli G, Micheli S, Cammelli D (2017) Sustained tocilizumab-induced hypofbrinogenemia and thrombocytopenia. Comment on: Tocilizumab induced hypofbrinogenemia: a report of 7 cases by Martis et al. Joint Bone Spine 84:649\u2013650. https:\/\/doi.org\/10.1016\/j.jbspin.2017.02.012","journal-title":"Joint Bone Spine"},{"key":"5714_CR9","unstructured":"Rocher F et al Tocilizumab induced hypofibrinogenemia. Fundamental and Clinical Pharmacology 29 (Suppl. 1): 72 abstr. PS2-050, Apr 2015. Available from: URL: https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/fcp.12108\/pdf [abstract] \u2013 France"},{"key":"5714_CR10","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1080\/14397595.2018.1428041","volume":"28","author":"H Imamura","year":"2018","unstructured":"Imamura H, Momohara S, Yano K, Sakuma Y, Nakayama M, Tobimatsu H et al (2018) Tocilizumab treatment in patients with rheumatoid arthritis is associated with reduced fibrinogen levels and increased blood loss after total knee arthroplasty. Mod Rheumatol 28:976\u2013980. https:\/\/doi.org\/10.1080\/14397595.2018.1428041","journal-title":"Mod Rheumatol"},{"key":"5714_CR11","doi-asserted-by":"publisher","first-page":"210","DOI":"10.56543\/aaeeu.2023.2.4.05","volume":"2","author":"\u017d Kardum","year":"2023","unstructured":"Kardum \u017d, \u0160imacA., Frketi\u0107 Marovi\u0107 K, Masle AM, MIlas Ahi\u0107 J (2023) Severe hypofbrinogenemia in a patient with giant cell arteritis treated with tocilizumab: case-based review. Anti Aging East Eur 2:210\u2013215. https:\/\/doi.org\/10.56543\/aaeeu.2023.2.4.05","journal-title":"Anti Aging East Eur"},{"key":"5714_CR12","doi-asserted-by":"publisher","unstructured":"Perl M, Herfeld K, Harrer DC, H\u00f6pting M, Schweiger M, Sterz U, Haematologica et al (2024) https:\/\/doi.org\/10.3324\/haematol.2023.284564","DOI":"10.3324\/haematol.2023.284564"},{"key":"5714_CR13","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s00296-015-3379-x","volume":"36","author":"T Okano","year":"2016","unstructured":"Okano T, Inui K, Tada M, Sugioka Y, Mamoto K, Wakitani S et al (2016) Levels of interleukin-1 beta can predict response to tocilizumab therapy in rheumatoid arthritis: the PETITE (predictors of effectiveness of tocilizumab therapy) study. Rheumatol Int 36:349\u2013357. https:\/\/doi.org\/10.1007\/s00296-015-3379-x","journal-title":"Rheumatol Int"},{"key":"5714_CR14","doi-asserted-by":"publisher","first-page":"e69944","DOI":"10.1371\/journal.pone.0069944","volume":"8","author":"S Mokuda","year":"2013","unstructured":"Mokuda S, Murata Y, Sawada N, Matoba K, Yamada A, Onishi M et al (2013) Tocilizumab induced acquired factor XIII deficiency in patients with rheumatoid arthritis. PLoS ONE 8:e69944. https:\/\/doi.org\/10.1371\/journal.pone.0069944","journal-title":"PLoS ONE"},{"key":"5714_CR15","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.thromres.2016.02.026","volume":"140","author":"M Souri","year":"2016","unstructured":"Souri M, Mokuda S, Inanami H, Osaki T, Takasugi K, Ichinose A (2016) Non-autoimmune combined factor XIII A and B subunit defciencies in rheumatoid arthritis patients treated with anti-interleukin-6 receptor monoclonal antibody (tocilizumab). Thromb Res 140:100\u2013105. https:\/\/doi.org\/10.1016\/j.thromres.2016.02.026","journal-title":"Thromb Res"},{"key":"5714_CR16","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s12185-012-1191-x","volume":"96","author":"M Matsuoka","year":"2012","unstructured":"Matsuoka M, Majima T, Onodera T, Ieko M, Souri M, Ichinose A et al (2012) Hemorrhagic-acquired factor XIII defciency associated with tocilizumab for treatment of rheumatoid arthritis. Int J Hematol 96:781\u2013785. https:\/\/doi.org\/10.1007\/s12185-012-1191-x","journal-title":"Int J Hematol"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-024-05714-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-024-05714-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-024-05714-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T11:04:48Z","timestamp":1733310288000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-024-05714-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,12]]},"references-count":16,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["5714"],"URL":"https:\/\/doi.org\/10.1007\/s00296-024-05714-1","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,12]]},"assertion":[{"value":"21 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the ethics committee of Eskisehir Osmangazi University with decision number of 06, decision dated July 13, 2021. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. For this type of retrospective study formal written informed consent is not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The preliminary results of this study was submitted to EULAR 2024 Congress held in Vienna in June 2024 and accepted as an abstract (\n                      \n                      ).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Previous related congress abstract publication"}},{"value":"Neither an AI nor an editing software was employed in the process of writing and editing this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}},{"value":"The authors declare that there is no conflict of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}